L&G Pharma Breakthrough UCITS ETF (ETR:ETLI)

Assets	19.79M
Expense Ratio	0.49%
PE Ratio	20.10
Dividend (ttm)	n/a
Dividend Yield	n/a
Ex-Dividend Date	n/a
Payout Frequency	n/a
Payout Ratio	n/a
1-Year Return	+21.90%

Volume	3,075
Open	13.17
Previous Close	13.08
Day's Range	12.99 - 13.17
52-Week Low	10.42
52-Week High	13.86
Beta	0.22
Holdings	46
Inception Date	Jan 23, 2018

About ETLI

The L&G Pharma Breakthrough UCITS ETF (the Fund) is an exchange traded fund (ETF) that aims to track the performance of the Solactive Pharma Breakthrough Value Index Net Total Return (the Index) subject to the deduction of the ongoing charges and other costs associated with operating the Fund.

• Asset Class: Equity
• Category: Health Care
• Stock Exchange: Deutsche Börse Xetra
• Ticker Symbol: ETLI
• Provider: L&G
• Index Tracked: Solactive Pharma Breakthrough Value Index

Performance

ETLI had a total return of 21.90% in the past year, including dividends. Since the fund's inception, the average annual return has been 3.50%.

Top 10 Holdings

26.04% of assets

Name	Symbol	Weight
Basilea Pharmaceutica AG	BSLN	2.71%
Eisai Co., Ltd.	4523	2.66%
Genmab A/S	GMAB	2.63%
AstraZeneca PLC	AZN	2.63%
Halozyme Therapeutics, Inc.	HALO	2.61%
United Therapeutics Corporation	UTHR	2.59%
Recordati Industria Chimica e Farmaceutica S.p.A.	REC	2.56%
Agios Pharmaceuticals, Inc.	AGIO	2.56%
Ligand Pharmaceuticals Incorporated	LGND	2.54%
Nippon Shinyaku Co., Ltd.	4516	2.54%

Data Sources: S&P Global Market Intelligence, Financial Modeling Prep, and more

Historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep. Several fund data points are also provided by Finnhub.

Last checked:

Sep 23, 2026

Data Sources Report a data error